04Jan
26Jun
Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity
Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today initiation of Phase 1b clinical study which is designed to provide proof-of-concept weight loss results, along with safety and tolerability, using an optimized formulation of the drug candidate XEN-101, in obese adults. The trial is expected to have top line results by the end of the year. The Phase 1b study is a double blinded, randomized, placebo...
18Apr
Xeno Biosciences Announces New CEO and Financing
Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today a change in executive leadership as of September 2023, and the completion of an additional financing round in February of 2024. This financing of $1.15M will fund a Phase 1b trial of the company’s lead compound, Xen-101, in obese individuals. The trial is expected to have top line results by the end of the year. The new...
11Aug